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a pilot project to collect this data and make it available for evaluation and planning 
processes in a standardized language according to CAP (Catalog for ambulatory 
procedures). METHODS: The data will be transferred into a new database in two 
data streams to ensure data protection. Data about the patient containing sex, age 
and other characteristics will be sent in a pseudonomyzed way in one data stream. 
Another will contain data about the procedures according to CAP and information 
about contract physicians, outpatient clinics and ambulatories. RESULTS: The new 
database will offer information about what until now has been more or less a black 
spot. It will give information about procedures performed in the ambulatory and 
outpatient sector for all stakeholders participating in this pilot project. CONCLU-
SIONS: Data about outpatient clinics and ambulatories have not been made accessible 
in one database for all participating stakeholders in a standardized language until now. 
The initiated pilot project and the database created therewith offer an opportunity to 
cover this lack of information.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Modeling Methods
PMC12
RULING OUT EXTENDLY DOMINATED OPTIONS USING  
AN ICER MATRIX
O’Day K, Meissner B, Bramley T
Xcenda, Palm Harbor, FL, USA
BACKGROUND: Incremental cost-effectiveness ratios (ICERs) represent the cost per 
unit of effectiveness of switching to a more costly and more effective option. In report-
ing results for cost-effectiveness (CE) analyses, options that are strictly dominated are 
ruled out and no ICERs should be reported. Additionally, some options may be ruled 
out by extended dominance (i.e., there is a linear combination of two options that 
dominates an option not otherwise excluded by strict dominance). In order to plot 
the CE efﬁciency frontier both strictly and extendedly dominated options must be 
excluded. Calculating strict dominance (e.g., in Excel) is straightforward. However 
calculating extended dominance is more complex. METHODS: We present a method 
to exclude extendedly dominated options using an ICER matrix. To form an ICER 
matrix all options are rank ordered by cost. For a CE analysis with N options, the 
ICER matrix is an N x N-1 sized table, where the ﬁrst column represents the ICER 
from the least costly option to each more costly option, the second column represents 
the ICER from the second least costly option to each more costly option, etc.. Negative 
ICERs, representing strictly dominated options, are excluded from the table. Extended 
dominance is established by calculating whether the ICER for a non-strictly dominated 
option is greater than the ICER for at least one more costly option. If so, the option 
is rule out by extended dominance, otherwise not. We show how to perform the 
required calculations in Excel and how to graphically plot the CE efﬁciency frontier 
once all dominated and extendedly dominated options have been excluded. CONCLU-
SIONS: Strictly dominated and extendedly dominated options must be ruled out in 
order to plot the CE efﬁciency frontier. The ICER matrix is a systematic method to 
rule out strictly and extendedly dominated options.
PMC13
THE COST-EFFECTIVENESS SENSITIVITY CURVE: QUANTIFYING  
THE EFFECT OF INDIVIDUAL PARAMETER UNCERTAINTY IN A 
PROBABILISTIC MODEL
O’Day K, Meissner B, Bramley T
Xcenda, Palm Harbor, FL, USA
BACKGROUND: The cost-effectiveness acceptability curve (CEAC) graphically 
depicts the joint uncertainty in a probabilistic model by transforming the incremental 
cost-effectiveness ratio into a net-beneﬁt framework to represent the probability that 
a strategy is cost-effective over a range of willingness-to-pay (WTP) thresholds. By 
characterizing the joint distribution of costs and effects for all model parameters, the 
CEAC simpliﬁes the presentation of uncertainty compared to deterministic one-way 
and multi-way sensitivity analyses and allows decision makers to identify the preferred 
strategy based on their WTP threshold. However, in some instances presenting only 
the joint uncertainty may be a limitation of the CEAC. METHODS: We propose a 
method to graphically present the uncertainty contributed by a single parameter within 
a probabilistic model called the cost-effectiveness sensitivity curve (CESC). Like the 
CEAC, the y-axis of the CESC represents the probability that a strategy is cost-
effective. However, instead of WTP, the x-axis represents a speciﬁed range of values 
for a single model parameter. The CESC is generated by varying the chosen parameter 
over the speciﬁed range of values and calculating the net-beneﬁt at each value for each 
simulation based on the sampled values of the remaining model parameters without 
resampling (note: to effect the net-beneﬁt transformation the CESC is based on a single 
WTP threshold). Computationally, the CESC requires an additional series of calcula-
tions for each simulation corresponding to the desired number of points on the curve. 
The advantage of the CESC is that it probabilistically describes the effect of uncer-
tainty of a single model parameter on cost-effectiveness. This is particularly useful for 
ex-ante pricing decisions and for early phase go/no-go decisions based on an antici-
pated range of effectiveness. CONCLUSIONS: The CESC is a useful tool in speciﬁc 
decision making contexts for quantifying the contribution of a single model parameter 
to uncertainty within a probabilistic model.
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MEDICATION LABEL EVALUATION PROCESS MODEL: USING THE 
STRUCTURAL EQUATION MODELING APPROACH TO BETTER 
PREDICT PURCHASE INTENTION
Dwibedi N, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: The objective of this study was to examine whether the Over-the-
Counter Medication Label Evaluation Process Model (OTC-LEPM) or its modiﬁed 
version explained consumer’s purchase intention better. METHODS: Data collected 
during an experimental ﬁeld study was reanalyzed using structural equation modeling 
(SEM). Purchase intention with regard to three OTC medications for pain was evalu-
ated using simulated product package labels for Acetaminophen, Ibuprofen and 
Aspirin. The experiment was conducted with consumers in the process of selecting an 
OTC product at local pharmacy stores. Endogenous variables were product knowl-
edge, product evaluation, attitude-toward-product label and purchase intention. An 
additional endogenous variable ease of use was used in the modiﬁed OTC-LEPM. 
Demographics collected were analyzed using descriptive analysis in SPSS. AMOS v17 
was used to conduct SEM and test whether OTC-LEPM or modiﬁed OTC-LEPM was 
the better model to explain the variables that predict purchase intention. RESULTS: 
A total of 336 consumers participated in the study. A chi-square value using the SEM 
approach for OTC-LEPM was 6262.390. The SEM for the modiﬁed OTC-LEPM 
indicated that iteration limit was reached (55000). Alternative model approach pro-
duced 3 models with slightly better chi-square value. A new model was built by 
combining alternative model approach and McFadden’s Choice Process. This model 
produced an improved ﬁt, producing a chi-square value of 4697 (df = 902, p < 0.0001). 
This model validated that knowledge signiﬁcantly causes attitude towards product 
label which directly and indirectly via product evaluation causes purchase intention 
and these causal links were statistically signiﬁcant. It indicated that only one exoge-
nous variable age was statistically signiﬁcant. CONCLUSIONS: The modiﬁed OTC-
LEPM may not be the best model to analyze consumer’s OTC medication purchase 
intention. Further research is needed to evaluate variables that can improve the under-
standing of consumer’s purchase intention.
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SYNCHRONIZATION OF RANDOM NUMBER STREAMS GREATLY 
ENHANCES EFFICIENCY OF PROBABILISTIC MODELS
Smolen LJ, Klein RW
Medical Decision Modeling Inc., Indianapolis, IN, USA
The inclusion of probabilistic components in health care models requires the imple-
mentation of random number sampling. Many microsimulation models use a single 
simple random number generator without concern for its properties. This limits the 
modeler’s ability to use the identical series of random numbers for alternative treat-
ment strategies or among comparators. Synchronization of model results between 
treatment arms within a model run is difﬁcult unless separate random streams are 
used for each source of variation. Synchronization of random number streams requires 
maintaining arrays of starting and current random number seeds. If each source of 
variation (e.g., times or probabilities of death and major events) has its own stream 
then the simulation of identical patients in all treatment arms is possible. By resetting 
the seed for each arm, the model results are impacted only by differences in model 
input point estimates (for ﬁrst-order analyses) or differences in the speciﬁed distribu-
tions of sampled model inputs (for second-order analyses). The impact of random 
number sampling is thus maximally correlated between treatments, and the differences 
in the occurrences of events common to both simulations, e.g., natural death, are not 
artiﬁcially inﬂated due to random sampling. Given a sufﬁcient number of replications, 
stochastic models usually produce stable results. This is because any further increase 
in the number of modeled replications will have minimal impact on the average-based 
model results. If the modeled result is the ratio of differences, such as an incremental 
cost effectiveness ratio (ICER), small differences in the denominator often drive the 
estimate, requiring a large number of replications. The allocation of common events, 
particularly natural death, to designated random streams minimizes the impact of 
random sampling on the model results. The number of model replications (and thus 
execution time) needed to produce stable ICERs may be reduced by as much as 90%.
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REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET 
IMPACT DRUGS
Aggarwal S1, White N2, Stevens CA3
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost effectiveness studies for the top ten highest selling drugs (∼$80–95B worldwide 
sales). METHODS: The Top 10 drugs were selected based on their worldwide sales. 
For this analysis, we segmented these drugs into categories as primary care, specialty, 
small molecules, biologics, therapy areas and availability of generic alternatives. We 
analyzed the cost effectiveness studies that were published in peer-reviewed journals. 
Search was conducted using generic names of the drugs and the phrase “cost effective-
ness” in abstract of the published study. RESULTS: During 2003–2008, the number 
of published studies on “cost effectiveness” have increased by more than 30%. Almost 
half of the published studies belong to—Remicade, Plavix and Enbrel. There is a large 
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variability in CERs for same drugs for different indications, in some cases also varying 
by biomarkers. Primary care drugs had lower and less variable CERs than specialty 
drugs. Variations also exist in methodology used by different groups in modeling cost 
effectiveness, especially for time horizon and comparator. Majority of primary care 
drugs were modeled for a time horizon of 35–40 years or lifetime to demonstrate cost 
effectiveness. Among the top 10 drugs, quetiapine and erythropoietin had the highest 
variability across different studies, and atorvatstatin, salmetrol/ﬂuticasone and clopi-
dogrel had the most consistent ICER values across studies. CONCLUSIONS: This 
analysis shows the range, variability and methods used for calculation of ICER values 
for these high budget impact drugs and provides lessons for executives and policy 
makers.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Patient-Reported 
Outcomes Studies
PMC17
A COMPARISON OF THE DISCRIMINTATIVE AND EVALUATIVE 
PROPERTIES OF THE SF-36 AND THE SF-6D INDEX
Mutebi A1, Brazier J2, Walters S2
1University of Arizona, Tucson, AZ, USA, 2University of Shefﬁeld, Shefﬁeld, UK
OBJECTIVES: To examine whether the move from the SF-36 to the SF-6D entails a 
loss in discriminative and evaluative strengths, the magnitude of that loss and whether 
it matters. METHODS: The study used relative validity (RV); a ratio of two F statis-
tics, and standardized response means (SRM) to evaluate sensitivity and responsive-
ness of the SF-36 scales and SF-6D index. An RV of 1 reﬂected the most sensitive/
responsive scale and the smaller the RV the less sensitive the measure would be. 
Cohen’s criterion for interpreting effect sizes was used to interpret the SRMs. The 
data used were initially collected for prior studies in seven diseases/conditions: chronic 
obstructive pulmonary disease, leg ulcers, the elderly in exercise, osteoarthritis, irri-
table bowel syndrome, migraine and obesity. Identiﬁed discriminative and evaluative 
variables were used to compare RVs and SRMs of the SF-36 scales and the SF-6D 
index. The mean RV differences and mean SRMs differences between the SF-36 scales 
and the SF-6D index represented the loss or gain in sensitivity. RESULTS: Data were 
available from a total of 10,089 subjects. No single SF-36 scale consistently had the 
largest RV or SRM, and there was no largest RV or SRM observed for the SF-6D 
index in any condition studied. Comparisons showed the SF-6D index was more 
discriminative with a mean RV difference of 0.09, (95% CI; 0.07 to 0.12) and more 
responsive with a mean SRM difference of 0.08, (95% CI; 0 to 0.16) than the SF-36 
scales. However, based on longitudinal RVs the index was less responsive with a mean 
RV difference of 0.07, (95% CI; 0.01 to 0.15) than the SF-36 scales. CONCLUSIONS: 
Moving from the SF-36 to the SF-6D index entails a loss in evaluative strength and a 
gain in discriminative strength, a loss/gain too small to matter given the merits of 
either instrument.
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ELECTRONIC PRO VERSUS PAPER PRO: WHAT DO THE PATIENTS 
THINK?
Ross J, Marcovitz M
Almac Clinical Technologies, Yardley, PA, USA
OBJECTIVES: To examine patients’ preferences and satisfaction on completing 
Patient Reported Outcome (PRO) assessments in studies that compared paper-admin-
istered to electronic versions. To identify which data collection method patients prefer. 
To explore aspects that makes the PRO experience more positive or negative for 
patients. METHODS: A large literature search was conducted to gather articles that 
utilized ePRO. From that, articles were identiﬁed and reviewed that compared paper 
to ePRO and assessed for patient satisfaction/preferences. RESULTS: 119 articles were 
identiﬁed that utilized ePRO; 26 (21.8%) compared paper to ePRO. Of the 26, 17 
(65.4%) reported on patient satisfaction/preferences. Electronic modalities consisted 
of handheld devices (70.6%), interactive voice response system (IVRS) (phone) (17.6 
%), electronic data capture system (5.9%) and both IVRS and handheld (5.9%). 
Patient satisfaction/preference was assessed through either interviews (41.2%) or 
questionnaires (58.8%). Patients reported preferring ePRO over paper in 88.2% of 
the articles. Positives aspects of paper included: familiarity, not dependent on technol-
ogy that may malfunction and ease of reading. Negative aspects of paper included: 
forgetting to complete and burden. Positive aspects of ePRO included: liked the diary’s 
appearance, convenient, ease of data entry, fast/efﬁcient, saves trees, reminders, overall 
survey experience, more fun/novel, easier on eye, more up-to-date, and comfort in 
handling. Negative aspects of ePRO included: system problems/failures, difﬁculty to 
read, difﬁcult to use, instructions could have been simpler, and inability to change 
reminder time or enter data late. CONCLUSIONS: As PRO are measures that come 
directly from the patients, it is important to identify their preferences and aspects of 
what makes their experiences more positive. These ﬁndings suggest that patients 
overall preferred ePRO and identiﬁed more positive aspects for ePRO. Both positive 
and negative aspects reported are equally valuable in identifying how PRO data col-
lection can be improved to provide patients with the most positive experiences.
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DIMENSIONS CHARACTERIZING GOOD HEALTH BY CHINESE  
IN CHINA
Li M1, Bao Z2, Zhou J2, Luo N3
1China Pharmaceutical University, Nanjing, Jiangsu, China, 2The First Afﬁliated Hospital of 
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OBJECTIVES: Health-related quality of life (HRQoL) instruments used in China are 
mainly from Western countries. Such instruments may not cover all the important 
health dimensions relevant to Chinese people as health is a culture-speciﬁc concept. 
However, there is a paucity of empirical data on what good health is to Chinese 
people. The objective of the current study is to identify health dimensions with which 
Chinese people use to deﬁne health. METHODS: A convenience sample of 200 adult 
Chinese (healthy persons: 80; inpatients: 120) were interviewed face to face. Open 
questions were used to elicit characteristics and life domains of good health. RESULTS: 
Fourteen health dimensions were identiﬁed. The 5 most frequently alluded dimensions 
were: mood (35.5%), absence of disease (33.3%), mobility (25.1%), ability to work 
(22.4%), and eating (17.5%). Other dimensions included vitality, pain or discomfort, 
physical ﬁtness, sleep, freedom, self-care, social relationship, enjoyment, and cogni-
tion. More proportion of healthy persons than patients quoted mood and self-care as 
dimensions of health while more patients emphasized ability to work. Males regarded 
eating as a health dimension more often than females while females quoted self-care 
and social relationship more frequently than males. With regard to age, older persons 
valued ability to work more than younger people while more younger people thought 
absence of pain or discomfort is a characteristic of good health. CONCLUSIONS: 
This study provides useful information for assessing the adequacy of HRQoL instru-
ments developed in Western countries for the Chinese population in China.
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THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D 
VISUAL ANALOGUE SCALE (VAS)
Clough LA, Ashcroft-Jones AJ, Furtado T, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: The EQ-5D has been translated into many languages. The Euroqol 
group have recently altered and clariﬁed the VAS scale. The objective of this study 
was to produce translations that are conceptually equivalent to the original and to 
other language versions, ensuring the relevance of the translations within the target 
cultures. METHODS: A standard methodology was employed: 1 forward and 1 back 
translation, review and developer review; or an in-country review and developer 
review; linguistic validation interviews with 8 subjects, a mix of healthy people and 
patients, a second developer review and 2 proofreadings. RESULTS: The translation 
process highlighted numerous cultural and linguistic issues, including: 1) Cognitive 
interviews showed that there was no clear Dutch word for scale, so an explanation 
likening the scale to a thermometer as in the previous 3L VAS was necessary; 2) In 
some cultures ‘mark an X on the scale’ was difﬁcult to render, and had to be amended 
by using alternative verb formations and formatting; 3) Though the new VAS mentions 
only ‘health’, in some languages, it was necessary to use “health state” to avoid confu-
sion, e.g. in Czech “health” alone means “good health.”; 4) In some languages the 
concepts of “health” and “health state” had different temporal associations. In 
Korean, “health” referred to a longer period of time, so “health today” had to be 
expressed by “health state today”; 5) Russian patients understood “health state” as 
the evaluation given by a doctor or test results, therefore “in your opinion” was added. 
CONCLUSIONS: The EQ-5D VAS has been translated and linguistically validated 
using a rigorous translation process. A number of cultural and linguistic issues became 
apparent and were resolved. The measure is now appropriate for use in multinational 
trials.
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PATIENT-REPORTED OUTCOMES IN PRODUCT DEVELOPMENT 
GUIDANCE
Mordin M1, Lewis S2, Gnanasakthy A3, Demuro-Mercon C2, Copley-Merriman K1, 
Fehnel S2
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, 
NC, USA, 3Novartis Pharma, East Hanover, NJ, USA
OBJECTIVES: Patient-reported outcomes (PRO) have received increasing attention 
from regulatory agencies regarding intended use of the data for promotional labeling 
claims. However, some disease areas and/or regulatory bodies necessitate the use of 
PRO data to substantiate product efﬁcacy for securing approval. Therefore, the 
research objective was to determine how many of the ﬁnal product development guid-
ance available from EMEA and FDA for clinical/medical research indicate PRO as a 
mandatory component of efﬁcacy. METHODS: Final guidance documents from the 
EMEA and FDA were reviewed for mention of PRO. EMEA Guidance documents 
that fell under the following categories were excluded: Clinical Pharmacology and 
Pharmacokinetics, Blood and Blood Forming Organs, Blood products (including 
biotech alternatives), and Herbals. Included in FDA Guidance review were those listed 
under the “Clinical/Medical” heading. The following data were abstracted from each 
guidance: guidance number, name, issue date, disease area, body system classiﬁcation, 
PRO requirement, PRO endpoint hierarchy, and a summary of the PRO language 
included in the guidance. PRO statements were then characterized within each of the 
following categories (yes/no): signs/symptoms, function/feeling, HRQOL, or patient 
global rating. RESULTS: Of the 134 ﬁnal guidance documents reviewed (EMEA = 81, 
FDA = 53), 52 mention PRO (EMEA n = 39; FDA n = 13). Within EMEA, PRO is 
